LISAvienna Newsletter 02/2017 – Get Connected
Is this email not displaying correctly?
View it in your browser


Newsletter March 2017

Dear reader,
Last week, numerous policy makers and key opinion leaders from industry and science celebrated the opening of the new IMP building. Boehringer Ingelheim invested some 52 million euros in the construction of this flagship facility for the Vienna Biocenter. 
Biotech is not the only topic on the rise in Vienna. Are you interested in an update on the regional medical device sector? Register for our Business Meeting on March 29. Together with the Medical University of Vienna, ÖGBMT, and AUSTROMED, we will showcase numerous innovative research results, opportunities for collaboration, and promising start-ups.
We hope you enjoy the brief roundup of life sciences news, deadlines, and events provided below. Be sure not to miss out on reading the spring edition of our biannual Highlights by the way!
All the best, 


Arsanis and Adimab enter into license agreement to target Respiratory Syncytial Virus (RSV) with monoclonal antibodies
Arsanis will initially focus on the selection of a lead RSV antibody candidate and has received a grant of up to $9.3 million from the Bill & Melinda Gates Foundation to advance the selected antibody to IND filing.
EUCODIS Bioscience and Tube Pharmaceuticals collaborate on tubulysins
EUCODIS has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Together, they produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.
Evercyte: New products for studying angiogenesis
Evercyte is a leading provider of standardizable and reproducible in vitro models and cell-based assays. Now, a stable and cost-effective growth factor VEGF165 is available for studying angiogenesis and screening for pro- and anti-angiogenic factors.
Technoclone: WKO to honor Veronika Binder with “Women Award 2017 – Export”
Technoclone is a world leading manufacturer focusing on research reagents and fully automated instruments for coagulation analysis. Currently, the company’s products are available in 43 countries, both on Technoclone label, but also as OEM products.
Viravaxx AG closes Series A investment round worth EUR 4.22 million
Viravaxx AG focuses on the development of antiviral vaccines for difficult to treat virus infections as well as diagnostic products for the detailed analysis of the immunological response to virus infections.


mySugr GmbH demonstrates clinically significant impact on diabetes management
At ATTD in Paris, mySugr and ProSciento, Inc. announced data from a retrospective observational clinical research study that demonstrates how consistent use of the mySugr app provides an opportunity for improved blood glucose control in high risk populations.
TAmiRNA launched thrombomiR™ - a simple and standardized test for analysis of platelet function using circulating microRNAs
The test enables researchers and clinicians to quantify platelet derived microRNAs in only a droplet of human plasma, to monitor anti-platelet therapy and estimate bleeding risk.
SCARLETRED Holding GmbH nominated for the Austrian Innovation Award 2017
The company offers the first globally scalable medical device platform enabling easy standardized remote skin tracking, objective digital skin analysis, and Big Data analytics from medical to industrial usage.
PIUR Imaging GmbH to release new software version for its tomographic ultrasound device PIUR tUS
The new personalized precision rehabilitation concept involves 31 clearly defined individual rehabilitation goals and 22 testing procedures. By the end of 2017, the concept will be gradually rolled out in all orthopedic, neurological and oncological rehabilitation centers of VAMED.


CeMM: First breath shapes the lung’s immune system
FH Technikum and ÖGBMT to stage 5th Medtec Summer Academy
IMP to celebrate the opening of its new building at the Vienna Biocenter
St. Anna, University of Vienna, University of Applied Arts and T-Systems to win the Austrian eAward 2017
Ludwig Boltzmann Institute for Cancer Research, Meduni Vienna, and Vetmeduni Vienna: Metabolic state of tumor cells control proliferation of tumor cell
Read more news at


Web: NEW in the Austrian Life Sciences Directory: Learn more about the Image Biopsy Lab GmbH. The company’s objective is the early detection, assessment, and follow-up of osteoarthritis (bone and cartilage wear) as well as osteoporosis (fracture risk) using conventional radiographs.

Mailings: We are restructuring our event mailing procedures. Please register here to be included in our event mailing list on business meetings organized by LISAvienna
Mark your calendar

LISAvienna Business Meeting in collaboration with MedUni Vienna, ÖGBMT and AUSTROMED
Vienna, March 29, 2017

DLA Piper In-house Counsel Training Seminar: Effective Dispute Resolution in Life Sciences
Vienna, April 21, 2017
MIND: New contact at DLA Piper to discuss details regarding this event

Sino European Development Foundation: Health Conference – Freud, Marco Polo and Hua Tuo
Vienna, October 3, 2017
Meet LISAvienna

BIO-Europe Spring 2017
Barcelona, March 19-22, 2017

conhIT – Connecting Healthcare IT
Berlin, April 25-27, 2017

WKO TECHTALK Biotech & Medtech: „Trends in the United Kingdom“and BioTrinity
London, May 8-10, 2017

BIO International Convention
San Diego, June 19-22, 2017

Have a look at our event list and find out where you can get deals on group exhibitions and discounted fees this year.
Latest Publication

The spring edition of our biannual Highlights publication is in print. Download the pdf version to read more about Pfizer’s PALLAS trial largely being managed by ABCSG in Vienna. This time, we also introduce solutions for critical care made in Vienna and feature Sanochemia’s photodynamic cancer diagnostic.

More publications are available at


aws BOB - Best of Biotech is an international life science business plan competition organized by the Life Science Austria (LISA) program run by the aws on behalf of the Austrian Federal Ministry for Science, Research and Economy. Submit your business idea by March 10, 2017!
Within the aws IP.Market call, up to EUR 200,000 are available per project to put innovations and technologies into practice beyond a company’s or research institute’s own realm. Submit your proposal by May 31, 2017.
Are you interested in receiving updates from aws on a regular basis? Register for a free newsletter. The current edition is available here.


March 10, 2017: aws - Business plan competition "Best of Biotech": Phase 1
March 14, 2017: Vienna Business Agency – Call Co-Create 2017
March 16, 2017: AkzoNobel – Imagine Chemistry Startup Challenge
March 28, 2017: H2020 – JTI IMI2: Call 10: Understanding hypoglycemia, big data &prostate cancer, pan-European pediatric clinical trials network, biomanufacturing, solute carrier gene-family, patient perspectives, autism spectrum disorders
April 19, 2017: DEBRA International - 'All-Priorities' Research Call

Register at for free mailings on European and other international funding initiatives in the life sciences.
Find additional deadlines at

EVENTS in Vienna

Vienna Business Agency: Business Meeting "Where to go? Smart and Assisted Living"

March 16, 2017, Vienna Business Agency, Mariahilfer Straße 20, 1070 Vienna
Please register by March 14.

FFG: Update on the Innovative Medicines Initiative 2

March 23, 2017, FFG, Sensengasse 1, 1090 Vienna
Please register by March 21.

ÖBVS: 1. Österreichischen D-A-CH Dreiländerkongress für klinische Forschung

March 24-25, AKH Wien, Medizinischer Universitätscampus, Hörsaalzentrum Ebene 7, Währinger Gürtel 18-20, 1090 Vienna
For more events be invited to
Your news placed here: Vienna-based organizations are invited to e-mail news and press releases to to contribute to LISAvienna's digital and print media.

Stay updated: Follow us on Twitter and LinkedIn and recommend our newsletter to colleagues and friends.
Copyright © LISAvienna 2017, All rights reserved.

Our mailing address is:

LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.

unsubscribe from this list  |  update subscription preferences